While outcomes-based contracts have been a hot buzzword for some time, little has been done on a broad scale to implement the alternative payment strategy, eyeforpharma reports.
Value-based pricing models in the U.S. have been mostly “few and far between,” according to the report, there are several exceptions.
Eyeforpharma cites a report by KPMG, which states some 25 drugs could be under value-based arrangements in the U.S., but most of them are pilot programs.
“We’re seeing a very uneven application of these deals,” Huron Consulting Managing Director Kenneth Beers told eyeforpharma. “While some companies are taking a more forward-looking role, others are still just hanging back, asking whether the hype can really be justified. What’s party contributing to this is that not all payers are doing it.”
To read the full report on eyeforpharma, click here.